EO Care Joins the Personify Health Partner Marketplace, Expanding Employer Access to Clinically Guided Cancer Symptom Management Solution

Employers using Personify Health can choose clinically responsible, evidence-based cannabinoid care to reduce unmanaged symptom burden, prescription reliance, and avoidable healthcare costs

BOSTON--(BUSINESS WIRE)--EO Care, Inc., the leader in cannabinoid-based symptom management, today announced that it has joined the Personify Health® Partner Marketplace to bring clinically-guided cancer symptom management to employers nationwide. Now, organizations using the Personify Health personalized health platform will have integrated access to EO’s clinically responsible, scalable cannabinoid-based care solution, an innovative way to support employees managing cancer-related symptoms such as pain, sleep disturbance, stress, and loss of appetite.

Employers can purchase EO as part of a broader health and wellbeing strategy for eligible populations, and as an integrated solution within Personify Health. EO Care’s program provides each member with an evidence-based, personalized care plan – specific product, dose, and time-of-use guidance – supported by ongoing access to a clinician-trained care team. This includes HIPAA-compliant messaging and phone-based support, personalized education, drug interaction and safety screening, ongoing symptom tracking using clinically validated PROMIS measures, and affordable, tested, federally legal hemp-derived products.

"This collaboration brings a clinically responsible, evidence-based approach to a category that employees are too often navigating without assistance," said Sean Collins, chief executive officer of EO Care. "Chronic symptom burden causes real human suffering, lost productivity, unnecessary prescription use, and avoidable cost. Employers need a responsible answer. EO Care has built a scalable, care-centered model informed by leaders across supportive oncology, employer health, and payer strategy – a model previously missing from the healthcare benefits market."

With patients sourced from clinicians at eight NCI-designated cancer centers and health systems, EO’s results distinguish it in a category long lacking clinical rigor. To date, 79% of cancer patients reach clinically meaningful improvement in anxiety and 56% in pain, based on validated PROMIS measures. The most symptom-burdened patients improve most, reaching meaningful improvement 74% of the time versus 48% for those with milder baselines, with an average symptom-score improvement of 8.3 points versus 2.5. Usability matches the clinical results, with over 92% of cancer patients onboarding unassisted.

EO Care is available now through Personify’s Partner Marketplace, which makes it easy for companies to integrate world-class solutions into their benefits programs, closing gaps in care across 25+ health and wellbeing categories while addressing the most common and costly health concerns.

About EO Care, Inc.
EO Care is the leader in cannabinoid-based symptom management. The company provides personalized, clinically responsible care through its unique, scalable digital health platform and affordable, medicalized and federally legal hemp-derived cannabinoid products. Board members, advisors and investors include Regina Benjamin, MD, MBA, former Surgeon General of the United States; Kristi Savacool, former CEO of AON Hewitt; William Fleming, former President of Humana, and Bill Van Faasen, former CEO of Blue Cross Blue Shield Massachusetts. For more information, visit https://eo.care.